Creative Planning Affimed N.V. Transaction History

Creative Planning

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 20, 2018	SELL	$1.65 - $2.5 $176,385 - $267,250	-106,900 Closed	0 $0
Q1 2018 Apr 18, 2018	BUY	$1.25 - $2.65 $8,625 - $18,285	6,900 Added 6.9%	106,900 $198,000
Q4 2017 Jan 17, 2018	BUY	$1.23 - $2.3 $6,150 - $11,500	5,000 Added 5.26%	100,000 $130,000
Q3 2017 Oct 17, 2017	BUY	$1.95 - $2.25 $185,250 - $213,750	95,000	95,000 $214,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.